Prunus Lifesciences India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.15 M
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -21.06%
- Profit Growth -30.39%
- Ebitda -37.82%
- Net Worth 2.69%
- Total Assets 11.55%
About Prunus Lifesciences India
Prunus Lifesciences India Private Limited (PLIPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 November 2013 and has a history of 11 years and two months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Kanithahalli Babu, Byraganahalli Reddy, and Byraganapalli Umadevi serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232KA2013PTC072199
- Company No.
072199
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2013
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Prunus Lifesciences India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kanithahalli Babu  | Director | 28-Nov-2013 | Current |
| Byraganahalli Reddy | Director | 28-Nov-2013 | Current |
| Byraganapalli Umadevi | Director | 28-Nov-2013 | Current |
Financial Performance of Prunus Lifesciences India.
Prunus Lifesciences India Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 21.06% decrease. The company also saw a substantial fall in profitability, with a 30.39% decrease in profit. The company's net worth moved up by a moderate rise of 2.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prunus Lifesciences India?
Unlock access to Prunus Lifesciences India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prunus Lifesciences India?
Unlock and access historical data on people associated with Prunus Lifesciences India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prunus Lifesciences India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prunus Lifesciences India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.